Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 9301–9350 of 75562
Also on February 19, 2025, Robert S. Boswell informed the Board of his decision to retire from the Board at the end of his current term and not stand for re-election as a director at the 2025 Annual Meeting.
As of February 22, 2025, Dian C. Taylor is no longer serving as the Company’s Chief Executive Officer and President.
On February 22, 2025, the Board of Directors (the “Board”) of Artesian Resources Corporation (the “Company”) appointed Nicholle R. Taylor to serve as the Company’s Chief Executive Officer and President.
the Board appointed Samraat S. Raha, the Company's Chief Operating Officer, to succeed Mr. Diaz as its President and Chief Executive Officer on the Effective Date.
the Board also appointed Mr. Raha to the Board to serve as a Class II director with a term expiring at the Company’s 2025 Annual Meeting of Stockholders as of the Effective Date to fill the vacancy on the Board that will be created by Mr. Diaz’ resignation.
Paul J. Diaz, the Company’s President and Chief Executive Officer, announced on February 24, 2025 that he will step down from those positions, and resign from the Company’s Board of Directors (the “Board”), on April 30, 2025
On February 23, 2025, the Board of Directors of Allegro MicroSystems, Inc. (the “Company”) appointed Michael C. Doogue as President and Chief Executive Officer and elected Mr. Doogue as a director of the Company, effective immediately.
Mr. Doogue succeeds Vineet Nargolwala, who is stepping down as President and Chief Executive Officer and as a member of the Board.
On February 19, 2025, the Board of Directors of the Company (the “Board”), approved an increase in the size of the Board from nine to ten members and appointed Barak Eilam as a director to fill the vacancy created by the increase.
On February 18, 2025, Michael Handley was appointed as Chief Operating Officer of Tivic Health Systems, Inc., a Delaware corporation (the “Company”), and President of the Company’s Tivic Biopharma division.
On February 20, 2025, pursuant to the amended and restated bylaws of Evoke Pharma, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) appointed Greg Pyszcymuka to serve as a Class I director, effective immediately, with an initial term expiring at the Company’s 2026 annual meeting of stockholders.
On February 24, 2025, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of Tobin “Toby” Schilke as Chief Financial Officer, which will be effective as of February 28, 2025.
Mr. Gengos will serve as the Chief Financial Officer of Terns, effective as of February 24, 2025.
On February 24, 2025, MasterCraft Boat Holdings, Inc. (the “Company”) announced that current President of the Company’s Pontoon segment, George Steinbarger, departed the Company effective February 24,2025.
increased the size of the Board from seven to eight directors and appointed Thomas Mullins to serve as an independent member of the Board to fill the resulting vacancy, effective February 18, 2025
the board of directors of the Company (the “Board”) increased the size of the Board from nine directors to ten directors and appointed Lloyd W. “Billy” Helms, Jr. to the resulting vacancy, effective immediately.
Jeffrey S. Kelly Departure On February 24, 2025, the Company terminated
On February 24, 2025, the Company terminated the employment of T. Hodge Walker, the Company’s Chief Operating Officer, without “cause,” effective immediately.
M. Christopher Doyle, the Company’s current President and Chief Executive Officer and a director of the Company, assumed the additional role of principal operating officer of the Company.
On February 19, 2025, Mr. Laurance Narbut notified the Board of Directors (the “Board”) of Barnwell Industries, Inc. (the “Company”) that he resigned as a director of the Company, effective February 19, 2025.
Nestor Jaramillo, Jr. is retiring from the Company, effective February 18, 2025
the Board appointed John L. Erb as the Company’s Interim Chief Executive Officer and President.
Larry J. Helling will retire from the Company’s board of directors and from his roles as Chief Executive Officer
Nick W. Anderson will become the Chief Financial Officer of the Company
Mr. Gipple will become the Chief Executive Officer of the Company at this time
at which time Mr. Todd W. Seyfert will become the Chief Executive Officer of the Company
Mr. Reid will resign as Vice President, General Counsel and Corporate Secretary of the Company effective as of June 30, 2025
Mr. Killoy will resign as the Chief Executive Officer of the Company on March 1, 2025
On February 19, 2025, Derek DiRocco, M.D., notified Werewolf Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company, effective upon the Company’s 2025 annual meeting of stockholders.
On February 19, 2025, the Board of the Company, upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Anil Singhal, Ph.D., as a director.
The Board also expanded its size from seven to eight directors and appointed Vincent Aurentz to serve as a Class I director of the Board.
the Board appointed Chris Cabell as President and Head of Research and Development of the Company.
On February 20, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Atea Pharmaceuticals, Inc. (the “Company”) elected Arthur Kirsch as a Class I director of the Company, effective immediately.
the Board of Directors (the “Board”) of Baker Hughes Company (the “Company”) announced the appointment of Ahmed Moghal as Executive Vice President and Chief Financial Officer of the Company, effective February 24, 2025
Nancy Buese who, by mutual agreement with the Board, ceased to serve as Chief Financial Officer of the Company effective February 24, 2025
Effective March 7, 2025, Elisa Palazzo will step down as the Chief Financial Officer of CarGurus, Inc. (the “Company”).
On February 21, 2025, the Company designated Jason Trevisan, the Company’s Chief Executive Officer, to serve as its principal financial officer and principal accounting officer effective upon Ms. Palazzo’s departure on March 7, 2025, and until such time that the Company appoints a successor Chief Financial Officer.
On February 20, 2025, the Board of Directors (the “Board”) of Carpenter Technology Corporation (the “Company”) appointed Julie A. Beck as a member of the Board effective immediately.
Retirement of Meg G. Crofton from the
Richard B. Cassidy II Director
David V. Goeckeler Chief Executive Officer
Ellyn J. Shook Director
Necip Sayiner Director
Devinder Kumar Director
the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) increased the size of the Board from eleven to twelve members and appointed Timothy P. Walbert to the Board, to be effective February 24, 2025.
Additionally, on February 19, 2025, Michele R. Kuhrt, Executive Vice President, Chief Transformation Officer of the Company, informed the Company of her intention to retire, effective August 31, 2025.
On February 19, 2025, Kellye I. Walker notified the Board of Directors (the “Board”) of Lincoln Electric Holdings, Inc. (the “Company”) of her intention to resign from the Board and not to stand for re-election upon the expiration of her current term, which expires at the Company’s 2025 annual meeting of shareholders.
On February 19, 2025, the Board of the Company increased its size from eleven to twelve members and elected N. Joy Falotico to fill the resulting vacancy.
Additionally, the Board appointed Mr. Richard Paolone as Chair of the Board, replacing Ms. Field in this role.
Ms. Siyun Yang was appointed as an independent director to fill the resulting vacancy, effective immediately.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.